Hutchmed (China) Limited Notice of Results (2703O)

TIDMHCM

RNS Number : 2703O

Hutchmed (China) Limited

31 January 2023

HUTCHMED to Announce 2022 Final Results

Hong Kong, Shanghai & Florham Park, NJ - Tuesday, January 31, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time (EST) / 8:30 am Greenwich Mean Time (GMT) / 4:30 pm Hong Kong Time (HKT).

Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management.

The conference call and audio webcast will take place at 8:00 am EST / 1:00 pm GMT / 9:00 pm HKT on Tuesday, February 28, 2023 and will be webcast live via the company website at www.hutch-med.com/event/ . The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website. A replay will also be available on the website shortly after the event.

About HUTCHMED

HUTCHMED (Nasdaq/A M:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. t is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. t has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch--med.com or follow us on LinkedIn .

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President         +852 2121 8200 
  Annie Cheng, Vice President             +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout   +1 (917) 570 7340 (Mobile) / bmiles@s oleburystrat .com 
  Europe - Ben Atwell / Alex Shaw,        +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) 
   FTI Consulting                          HUTCHMED@fticonsulting.com 
  Asia - Zhou Yi,                         +852 97 83 6894 (Mobile) / HUTCHMED@brunswickgroup.com 
   Brunswick 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley, 
   Panmure Gordon (UK) Limited            +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFBLFXXFLBBBL

(END) Dow Jones Newswires

January 31, 2023 03:30 ET (08:30 GMT)

HUTCHMED China (AQSE:HCM.GB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024